299 related articles for article (PubMed ID: 29303226)
1. Dydrogesterone has no effect on uterine fibroids when used to prevent miscarriage in pregnant women with uterine fibroids.
Wang S; Wang XT; Liu RH; Liu M; Wu YR; Huang XY; Zhao N; Mu YL
Ginekol Pol; 2017; 88(12):679-685. PubMed ID: 29303226
[TBL] [Abstract][Full Text] [Related]
2. Dydrogesterone support in threatened miscarriage.
El-Zibdeh MY; Yousef LT
Maturitas; 2009 Dec; 65 Suppl 1():S43-6. PubMed ID: 20007011
[TBL] [Abstract][Full Text] [Related]
3. Adverse obstetric outcomes in pregnant women with uterine fibroids in China: A multicenter survey involving 112,403 deliveries.
Zhao R; Wang X; Zou L; Li G; Chen Y; Li C; Zhang W
PLoS One; 2017; 12(11):e0187821. PubMed ID: 29136018
[TBL] [Abstract][Full Text] [Related]
4. Dydrogesterone use in early pregnancy.
Mirza FG; Patki A; Pexman-Fieth C
Gynecol Endocrinol; 2016; 32(2):97-106. PubMed ID: 26800266
[TBL] [Abstract][Full Text] [Related]
5. Dydrogesterone in threatened miscarriage: a Malaysian experience.
Pandian RU
Maturitas; 2009 Dec; 65 Suppl 1():S47-50. PubMed ID: 20005647
[TBL] [Abstract][Full Text] [Related]
6. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study.
Ghosh S; Chattopadhyay R; Goswami S; Chaudhury K; Chakravarty B; Ganesh A
J Obstet Gynaecol Res; 2014 Jul; 40(7):1871-6. PubMed ID: 25056464
[TBL] [Abstract][Full Text] [Related]
7. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
8. Oral dydrogesterone for prevention of miscarriage in threatened miscarriage: a randomized, double-blind, placebo-controlled trial.
Kuptarak A; Phupong V
J Matern Fetal Neonatal Med; 2024 Dec; 37(1):2333929. PubMed ID: 38570191
[TBL] [Abstract][Full Text] [Related]
9. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage.
Siew JYS; Allen JC; Hui CYY; Ku CW; Malhotra R; Østbye T; Tan TC
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():319-324. PubMed ID: 30077119
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
11. Endometrial implantation factors in women with submucous uterine fibroids.
Ben-Nagi J; Miell J; Mavrelos D; Naftalin J; Lee C; Jurkovic D
Reprod Biomed Online; 2010 Nov; 21(5):610-5. PubMed ID: 20880745
[TBL] [Abstract][Full Text] [Related]
12. Are Women With Uterine Fibroids at Increased Risk for Adverse Pregnancy Outcome?
Ezzedine D; Norwitz ER
Clin Obstet Gynecol; 2016 Mar; 59(1):119-27. PubMed ID: 26670833
[TBL] [Abstract][Full Text] [Related]
13. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids.
Luyckx M; Squifflet JL; Jadoul P; Votino R; Dolmans MM; Donnez J
Fertil Steril; 2014 Nov; 102(5):1404-9. PubMed ID: 25241376
[TBL] [Abstract][Full Text] [Related]
14. Dydrogesterone in threatened abortion: pregnancy outcome.
Omar MH; Mashita MK; Lim PS; Jamil MA
J Steroid Biochem Mol Biol; 2005 Dec; 97(5):421-5. PubMed ID: 16293412
[TBL] [Abstract][Full Text] [Related]
15. Dydrogesterone in the reduction of recurrent spontaneous abortion.
El-Zibdeh MY
J Steroid Biochem Mol Biol; 2005 Dec; 97(5):431-4. PubMed ID: 16253504
[TBL] [Abstract][Full Text] [Related]
16. [Uterine leiomyomas during pregnancy and its impact on obstetric outcome].
Morgan Ortiz F; Piña Romero B; Elorriaga García E; Báez Barraza J; Quevedo Castro E; Peraza Garay Fde J
Ginecol Obstet Mex; 2011 Aug; 79(8):467-73. PubMed ID: 21966843
[TBL] [Abstract][Full Text] [Related]
17. Treatment options for threatened miscarriage.
Qureshi NS
Maturitas; 2009 Dec; 65 Suppl 1():S35-41. PubMed ID: 19945236
[TBL] [Abstract][Full Text] [Related]
18. Dydrogesterone and the immunology of pregnancy.
Raghupathy R; Szekeres-Bartho J
Horm Mol Biol Clin Investig; 2016 Aug; 27(2):63-71. PubMed ID: 26812877
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of dydrogesterone for the treatment of threatened miscarriage.
Carp H
Gynecol Endocrinol; 2012 Dec; 28(12):983-90. PubMed ID: 22794306
[TBL] [Abstract][Full Text] [Related]
20. Present and future aspects of dydrogesterone in prevention or treatment of pregnancy disorders: an outlook.
Schindler AE
Horm Mol Biol Clin Investig; 2016 Aug; 27(2):49-53. PubMed ID: 27662647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
